| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29, 2024 | NBIX Neurocrine Biosciences Inc | Sherwin Stephen A | Director | Sell | 40,000 | $133.46 | $5,338,564.50 | -43.0% | +13.3% | -8.1% | |
| May 29, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Director | Sell | 7,200 | $268.09 | $1,930,282.98 | -36.7% | +30.4% | +19.7% | |
| May 28, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 2,052 | $809.00 | $1,660,068.00 | - | +17.7% | -11.0% | |
| May 28, 2024 | PRGO Perrigo Co Plc | Andersen Svend47 | EVP &President Chci | Buy | 1,000 | $27.90 | $27,900.00 | +1.0% | +6.9% | -0.8% | |
| May 28, 2024 | LNTH Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | Sell | 18,373 | $79.19 | $1,454,989.48 | -13.5% | +35.1% | -6.6% | |
| May 28, 2024 | COLL Collegium Pharmaceutical, Inc | Tupper Colleen45 | EVP &Chief Financial Officer | Sell | 19,710 | $34.21 | $674,367.80 | -13.1% | +9.3% | -15.9% | |
| May 28, 2024 | VTRS Viatris Inc | Roman Brian | Chief Legal Officer | Sell | 89,419 | $10.38 | $928,428.54 | -56.9% | +13.1% | -17.3% | |
| May 28, 2024 | LNTH Lantheus Holdings, Inc. | McHugh Julie53 | Director | Sell | 2,500 | $78.50 | $196,250.00 | -8.0% | +35.1% | -6.6% | |
| May 28, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,502 | $17.33 | $43,359.66 | -1.6% | -16.0% | +179.3% | |
| May 24, 2024 | BCRX Biocryst Pharmaceuticals Inc | Aselage Steve80 | Director | Buy | 2,500 | $6.40 | $16,000.00 | New | +29.4% | +72.8% | |
| May 24, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 92,563 | $809.21 | $74,902,997.79 | - | +18.2% | -11.6% | |
| May 24, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Director | Sell | 7,200 | $274.16 | $1,973,943.43 | -37.7% | +27.1% | +12.7% | |
| May 24, 2024 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 108,016 | $33.91 | $3,662,548.45 | -30.6% | +5.2% | -15.7% | |
| May 23, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 50,767 | $809.99 | $41,120,962.83 | - | +17.8% | -11.7% | |
| May 22, 2024 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 37,000 | $0.27 | $9,990.00 | - | - | - | |
| May 22, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Director | Sell | 3,600 | $277.20 | $997,918.38 | -30.1% | +25.5% | +11.7% | |
| May 22, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 12,974 | $804.18 | $10,433,483.22 | - | +18.3% | -10.9% | |
| May 21, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 186,259 | $805.45 | $150,021,693.92 | - | +14.8% | -9.7% | |
| May 21, 2024 | MIRA Mira Pharmaceuticals, Inc. | Aminov Erez51 | Chief Executive Officer | Buy | 8,700 | $0.94 | $8,176.00 | +0.3% | +74.5% | +18.6% | |
| May 21, 2024 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 1,089 | $5.78 | $6,294.42 | -2.2% | +133.6% | +24.1% | |
| May 21, 2024 | ETST Earth Science Tech, Inc. | Flores Ernesto L | CFO | Buy | 45,834 | $0.20 | $9,166.80 | +808.9% | - | - | |
| May 21, 2024 | HIMS Hims & Hers Health, Inc. | Payne Christopher D77 | Director | Buy | 110,000 | $17.74 | $1,951,763.00 | New | -5.7% | +230.3% | |
| May 21, 2024 | ANIP Ani Pharmaceuticals Inc | Mutz Christopher | Head Of Rare Disease | Sell | 2,000 | $61.61 | $123,220.00 | -2.3% | -0.8% | -4.3% | |
| May 21, 2024 | ELAN Elanco Animal Health Inc | Doyle William F53 | Director | Buy | 15,000 | $16.98 | $254,700.00 | +24.5% | -11.3% | -24.4% | |
| May 21, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Director | Sell | 7,200 | $274.97 | $1,979,771.89 | -45.8% | +26.7% | +12.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.